ARTICLE | Clinical News
Indevus Phase II pain data
December 3, 2002 8:00 AM UTC
IDEV said its IP 751 (formerly CT-3) synthetic cannabinoid gave a significant reduction in neuropathic pain in a placebo-controlled Phase II study of 21 patients with chronic pain resulting from spina...